Literature DB >> 26543098

Genome-Edited Human Pluripotent Stem Cell-Derived Macrophages as a Model of Reverse Cholesterol Transport--Brief Report.

Rajat M Gupta1, Torsten B Meissner1, Chad A Cowan, Kiran Musunuru.   

Abstract

OBJECTIVE: To create isogenic human pluripotent stem cell-derived macrophages with and without ABCA1 expression as a model for reverse cholesterol transport. APPROACH AND
RESULTS: The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) genome-editing system was used to introduce frameshift mutations into the coding sequence of ATP-binding cassette, subfamily A, member 1. Individual human pluripotent stem cell clones with deleterious mutations were identified, expanded, and differentiated into mature macrophages with a cytokine-based, feeder-free differentiation protocol. Wild-type cells demonstrated effective cholesterol efflux to apoAI acceptor, whereas ABCA1(-/-) cells displayed significantly reduced efflux ability and increased expression of proinflammatory cytokines.
CONCLUSIONS: Human pluripotent stem cell-derived macrophages capable of reverse cholesterol transport can be rapidly generated and genetically edited with CRISPR/Cas9. Introduction of homozygous frameshift mutations results in loss of ABCA1 expression in differentiated macrophages and subsequent reduction of cholesterol efflux capability. This facile genome-editing approach and differentiation protocol pave the way for future studies of the molecular determinants of reverse cholesterol transport and other macrophage properties.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  cell differentiation; cholesterol; genetics; macrophages; stem cells

Mesh:

Substances:

Year:  2015        PMID: 26543098      PMCID: PMC4690765          DOI: 10.1161/ATVBAHA.115.305956

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

1.  Functional analysis and transcriptomic profiling of iPSC-derived macrophages and their application in modeling Mendelian disease.

Authors:  Hanrui Zhang; Chenyi Xue; Rhia Shah; Kate Bermingham; Christine C Hinkle; Wenjun Li; Amrith Rodrigues; Jennifer Tabita-Martinez; John S Millar; Marina Cuchel; Evanthia E Pashos; Ying Liu; Ruilan Yan; Wenli Yang; Sager J Gosai; Daniel VanDorn; Stella T Chou; Brian D Gregory; Edward E Morrisey; Mingyao Li; Daniel J Rader; Muredach P Reilly
Journal:  Circ Res       Date:  2015-04-22       Impact factor: 17.367

2.  HDL cholesterol efflux capacity and incident cardiovascular events.

Authors:  Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

3.  ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages.

Authors:  J F Oram; R M Lawn; M R Garvin; D P Wade
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

4.  Cholesterol efflux assay.

Authors:  Hann Low; Anh Hoang; Dmitri Sviridov
Journal:  J Vis Exp       Date:  2012-03-06       Impact factor: 1.355

5.  Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease.

Authors:  Leelamma M Panicker; Diana Miller; Tea Soon Park; Brijesh Patel; Judi L Azevedo; Ola Awad; M Athar Masood; Timothy D Veenstra; Ehud Goldin; Barbara K Stubblefield; Nahid Tayebi; Swamy K Polumuri; Stefanie N Vogel; Ellen Sidransky; Elias T Zambidis; Ricardo A Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

6.  Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs.

Authors:  Cory Smith; Athurva Gore; Wei Yan; Leire Abalde-Atristain; Zhe Li; Chaoxia He; Ying Wang; Robert A Brodsky; Kun Zhang; Linzhao Cheng; Zhaohui Ye
Journal:  Cell Stem Cell       Date:  2014-07-03       Impact factor: 24.633

7.  Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing.

Authors:  Adrian Veres; Bridget S Gosis; Qiurong Ding; Ryan Collins; Ashok Ragavendran; Harrison Brand; Serkan Erdin; Chad A Cowan; Michael E Talkowski; Kiran Musunuru
Journal:  Cell Stem Cell       Date:  2014-07-03       Impact factor: 24.633

8.  Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver.

Authors:  Miranda Van Eck; Jaap Twisk; Menno Hoekstra; Brechje T Van Rij; Christian A C Van der Lans; I Sophie T Bos; J Kar Kruijt; Folkert Kuipers; Theo J C Van Berkel
Journal:  J Biol Chem       Date:  2003-03-14       Impact factor: 5.157

Review 9.  Genome editing of human pluripotent stem cells to generate human cellular disease models.

Authors:  Kiran Musunuru
Journal:  Dis Model Mech       Date:  2013-06-10       Impact factor: 5.758

10.  An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.

Authors:  Michael Ditiatkovski; Wilissa D'Souza; Rajitha Kesani; Jaye Chin-Dusting; Judy B de Haan; Alan Remaley; Dmitri Sviridov
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more
  16 in total

Review 1.  Genome editing in cardiovascular diseases.

Authors:  Alanna Strong; Kiran Musunuru
Journal:  Nat Rev Cardiol       Date:  2016-09-09       Impact factor: 32.419

Review 2.  Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.

Authors:  Ronen Ben Jehuda; Yuval Shemer; Ofer Binah
Journal:  Stem Cell Rev Rep       Date:  2018-06       Impact factor: 5.739

3.  Transcriptome-Wide Analysis Reveals Modulation of Human Macrophage Inflammatory Phenotype Through Alternative Splicing.

Authors:  Jennie Lin; Yu Hu; Sara Nunez; Andrea S Foulkes; Benjamin Cieply; Chenyi Xue; Mark Gerelus; Wenjun Li; Hanrui Zhang; Daniel J Rader; Kiran Musunuru; Mingyao Li; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-05-26       Impact factor: 8.311

Review 4.  Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association.

Authors:  Kiran Musunuru; Farah Sheikh; Rajat M Gupta; Steven R Houser; Kevin O Maher; David J Milan; Andre Terzic; Joseph C Wu
Journal:  Circ Genom Precis Med       Date:  2018-01-12

Review 5.  Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.

Authors:  Alexandra C Chadwick; Kiran Musunuru
Journal:  Curr Atheroscler Rep       Date:  2017-07       Impact factor: 5.113

Review 6.  Genome Editing for the Study of Cardiovascular Diseases.

Authors:  Alexandra C Chadwick; Kiran Musunuru
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

7.  Reporting Sex and Sex Differences in Preclinical Studies.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

8.  CRISPR/Cas9-Mediated Gene Editing in Human iPSC-Derived Macrophage Reveals Lysosomal Acid Lipase Function in Human Macrophages-Brief Report.

Authors:  Hanrui Zhang; Jianting Shi; Melanie A Hachet; Chenyi Xue; Robert C Bauer; Hongfeng Jiang; Wenjun Li; Junichiro Tohyama; John Millar; Jeffrey Billheimer; Michael C Phillips; Babak Razani; Daniel J Rader; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-09-07       Impact factor: 8.311

9.  Human Macrophage Genetic Engineering.

Authors:  Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01       Impact factor: 8.311

Review 10.  Genome Editing: The Recent History and Perspective in Cardiovascular Diseases.

Authors:  Kiran Musunuru
Journal:  J Am Coll Cardiol       Date:  2017-12-05       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.